Skip to main content

Branded

  • NACDS, NCPA reach out to maintain TRICARE beneficiary access to Rx meds

    WASHINGTON – In their ongoing commitment to protect TRICARE beneficiaries’ access to prescription medications, the National Association of Chain Drug Stores and the National Community Pharmacists Association sent letters last week to the chairmen and ranking members of the House Armed Services Committee and the Senate Armed Services Committee urging them to protect TRICARE beneficiary access by refusing to further increase retail community pharmacist copayments. 

  • Pfizer introduces first and only biosimilar monoclonal antibody therapy

    NEW YORK - The United States Food and Drug Administration on Tuesday approved Celltrion’s Inflectra (biosimilar infliximab) across all eligible indications of the reference product, Remicade (infliximab). Inflectra is now the first and only biosimilar monoclonal antibody (mAb) therapy, and only the second biosimilar, to be approved in the U.S.
     

  • Pfizer walks away from Allergan deal following Treasury move on inversion

    NEW YORK - Pfizer on Wednesday announced that the merger agreement between Pfizer and Allergan has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.
     

  • Female Health Company and Aspen Park Pharmaceuticals announce merger

    CHICAGO - The Female Health Company on Wednesday announced that it has entered into a definitive merger agreement with Aspen Park Pharmaceuticals, a privately held company focused on the development and commercialization of oncology and men’s and women’s health therapeutics and consumer health products. 
     

  • Gilead’s new HIV drug Descovy gets FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for HIV from Gilead Sciences. The company announced Monday that it had received the agency’s approval for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg, F/TAF). 
     

  • Dr. Reddy’s, CutisPharma announce API supply, joint development partnerships

    WILMINGTON, Mass. — Dr. Reddy’s Laboratories and specialty pharmaceutical company CutisPharma announced Tuesday agreements for active pharmaceutical ingredient (API) supply and joint development as a way to advance several of CutisPharma’s research and development programs. 
     

  • Walgreens study: Pharmacy interventions improve adherence, lower costs

    DEERFIELD, Ill. — Walgreens on Monday released the results of a study that showed its pharmacy patients who used a multi-faceted medication adherence program had a 3% higher medication adherence rate and lower healthcare costs than those who use other pharmacies. The results were published in Population Health Management. 
     

  • Flu incidence abating in Oregon, California according to latest Walgreens Flu Index report

    DEERFIELD, Ill. - The incidence of flu is beginning to abate across California and Oregon, according to the latest Walgreens Flu Index report. However, flu activity is still relatively high across Wyoming, Montana and Kentucky, according to the report. 
     
    The top 10 markets with flu activity for the week of March 27 were: 
     
    1. El Paso, Texas (Las Cruces, N.M.);
    2. Harlingen – Weslaco – Brownsville – McAllen, Texas;
    3. Louisville, Ky.;
X
This ad will auto-close in 10 seconds